Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Medicover misses revenue growth in Q3 and warns of a slowdown

Medicover reports revenue growth of 12.1% (organic 12.4%) in the third quarter of 2025, below consensus expectations of 14.5% (organic 14.3%). The Healthcare Services segment grew 9.6% with strong gains in Poland and Romania; India showed a reported decline of -1.5% due to currency effects. Diagnostic Services increased by 17.8%, lab test volumes rose 17.4%, and the adjusted EBITDA margin improved to 17.2%. Acquisitions supported revenue and margins, and leverage fell to 3.2x. Management expects a slowdown from Q4 for several quarters because of more cautious consumer behaviour and the ramp-up of two new hospitals in India. » Altro su de.investing.com
Medicover increases revenue and margin in the second quarter of 2025

Medicover recorded revenue growth of 17.1% in the second quarter of 2025 and improved its adjusted EBITDA margin to 16.9%. The main growth drivers were the Healthcare Services division and business in Poland, while new units in India and Romania continued to weigh on margins. Net debt increased slightly due to acquisitions, but management expects a relaxation in the second half of the year. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, MEDICOVER AB ha già distribuito 0,0184€ di dividendi. L'ultimo pagamento è avvenuto a maggio.

Dati finanziari dell'azienda

Nell'ultimo trimestre, MEDICOVER AB ha registrato ricavi pari a 631,87M€ e un utile netto di 24,17M€

(EUR)	giu 2026	YoY
Ricavi	+631,87M	5,89%
Utile lordo	+151,65M	6,72%
Utile netto	+24,17M	26,56%
EBITDA	+105,67M	46,16%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+2,92Mld€
Numero di azioni	133,34M
Massimo/minimo a 52 settimane	+21,87€ - +10,76€
Rendimento da dividendo	+0,08%
Dividendi TTM	+0,0184€
Beta	1,5
Rapporto P/E	+38,84
Rapporto PEG	+0,42
Rapporto P/B	+6,15
Rapporto P/S	+1,33

Profilo aziendale

Medicover AB (publ) bietet Gesundheits- und Diagnosedienstleistungen in Deutschland, Schweden, Polen, der Türkei, Weißrussland, Bulgarien, Georgien, Ungarn, Serbien, Moldawien, der Ukraine und Indien an. Das Unternehmen ist in zwei Segmenten tätig: Gesundheitsdienstleistungen und diagnostische Dienstleistungen. Die diagnostischen Dienstleistungen des Unternehmens umfassen verschiedene Tests, darunter Allergie- und Autoimmundiagnostik, Bakteriologie, Parasitologie, Biochemie und Immunchemie, Blutgruppendiagnostik/Transfusionsmedizin, Tumormarker, klinische Chemie, Zytologie, Hämatologie, Histopathologie, Humangenetik, Hygiene, Immunologie und Immunchemie, Infektionskrankheiten, Mikrobiologie, Molekularbiologie und Pharmakologie/Toxikologie. Das Unternehmen betreibt 97 klinische Labors, 733 Blutabnahmestellen und 26 Kliniken in 10 Ländern sowie 117 medizinische Kliniken, 20 Fruchtbarkeitskliniken, 52 Zahnkliniken, 25 Krankenhäuser und 25 Fitnessstudios. Das Unternehmen bedient Firmen- und Privatkunden sowie Patienten und öffentliche Kostenträger. Medicover AB (publ) wurde 1995 gegründet und hat seinen Hauptsitz in Stockholm, Schweden.